Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
The DOI matches its Crossref record, with a small difference in title or year; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Warfarin is very effective in preventing recurrent venous thromboembolism but is also associated with a substantial risk of bleeding. After three months of conventional warfarin therapy, a lower dose of anticoagulant medication may result in less bleeding and still prevent recurrent venous thromboembolism. METHODS: We conducted a randomized, double-blind study, in which 738 patients who had completed three or more months of warfarin therapy for unprovoked venous thromboembolism were randomly assigned to continue warfarin therapy with a target international normalized ratio (INR) of 2.0 to 3.0 (conventional intensity) or a target INR of 1.5 to 1.9 (low intensity). Patients were followed for an average of 2.4 years. RESULTS: Of 369 patients assigned to low-intensity therapy, 16 had recurrent venous thromboembolism (1.9 per 100 person-years), as compared with 6 of 369 assigned to conventional-intensity therapy (0.7 per 100 person-years; hazard ratio, 2.8; 95 percent confidence interval, 1.1 to 7.0). A major bleeding episode occurred in nine patients assigned to low-intensity therapy (1.1 events per 100 person-years) and eight patients assigned to conventional-intensity therapy (0.9 event per 100 person-years; hazard ratio, 1.2; 95 percent confidence interval, 0.4 to 3.0). There was no significant difference in the frequency of overall bleeding between the two groups (hazard ratio, 1.3; 95 percent confidence interval, 0.8 to 2.1). CONCLUSIONS: Conventional-intensity warfarin therapy is more effective than low-intensity warfarin therapy for the long-term prevention of recurrent venous thromboembolism. The low-intensity warfarin regimen does not reduce the risk of clinically important bleeding.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
In the citing paper
“However, it should be noted that patients considered to have a ' high risk of bleeding ' were excluded from the randomized trial described in the analysis above. 316”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181 · cited 1×
“[7] Hazard ratios associated with low-intensity therapy as compared with conventional-intensity therapy (with 95 percent confidence intervals) and log-rank tests were used to compare the treatment groups.”
MethodNonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079 · cited 1×
“Assays for factor V Leiden [4] and the G20210A mutation in the prothrombin gene [5] were performed in a central laboratory by technologists who were unaware of the patient's treatment-group assignment and clinical course.”
MethodOral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804 · cited 1×
“0 per 100 patient-years among those assigned to low-intensity therapy, [6] an average of 2.”
BackgroundSelf-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072 · cited 5×
“As in other studies, [2,10] factor V Leiden and prothrombin-gene mutations were not associated with a higher risk of recurrent thromboembolism, although all patients in our study were treated with anticoagulant therapy.”
BackgroundResultInfluentialSelf-citationNatural History of Venous Thromboembolism
Kearon, C. (2003) · Circulation · doi:10.1161/01.cir.0000078464.82671.78 · Cited by 1,048
Self-citationLong-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808 · cited 2×
“Collectively, the results of our study and the three other trials that have evaluated extended treatment of patients who have had unprovoked venous thromboembolism [2,3,9] suggest that low-intensity anticoagulant therapy reduces the risk of recurrent thrombosis by about 75 percent, whereas conventional-intensity thera…”
BackgroundResultBeyth, R. J., Quinn, L. M., & Landefeld, C. S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00198-3 · Cited by 773
Research works printed but not linked: 3
- Kearon C, 2003, Circulation, 107, I
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
Cited by
Items 701–748 of 748
Rickles, F. R., & Levine, M. N. (2007) · Elsevier eBooks · doi:10.1016/b978-141602401-9.10023-9 · Cited by 1
More Than an Aspirin a Day to Keep Recurrent Venous Thromboembolism Away
Linkins, L. (2017) · The Hematologist · doi:10.1182/hem.v14.4.7448
Tôn, N. Đ., Hoa, N. T., Anh, N. P., Vu, N. P., Thảo, L. T. B., & Hà, N. H. (2020) · Vietnam Journal of Biotechnology · doi:10.15625/1811-4989/17/4/14568
Treatment of Antiphospholipid Syndrome
Sciascia, S., & Khamashta, M. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801917-7.00063-2
Extended therapy and secondary prevention of venous thromboembolic complications
Petrikov, A. S., & Игоревич, П. И. (2020) · I P Pavlov Russian Medical Biological Herald · doi:10.23888/pavlovj2020284548-566
Nguyen (2013) · Journal of Hematology · doi:10.4021/jh100e
“Rates of symptomatic TE event were similar to results in the ELATE trial, but slightly lower than in most other studies and rates of bleeding events were similar to most studies [4, 5, 8-10].”
ResultLinkins, L., & Kearon, C. (2009) · Wiley eBooks · doi:10.1002/9781444309768.ch64
Self-citationANTITHROMBOTIC EFFECTS OF SULODEXIDE: A REVIEW ARTICLE
Frati-Munari, A. C., Lecuona-Huet, N. E., & Majluf‐Cruz, A. (2021) · INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · doi:10.36106/ijsr/8746403
Triple Therapy: Risky but Sometimes Necessary
Sørensen, R., & Gislason, G. (2013) · Springer eBooks · doi:10.1007/978-1-4471-5424-2_6
Weitz, J. I. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5223-4.00034-2
Self-citationPulmonary Complications of Hematologic Disease
Machado, R. F., & Gladwin, M. T. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4710-0.00084-5 · Cited by 1
Pernod, G. (2014) · doi:10.2217/fmeb2013.13.33
Tratamento anticoagulante de longa duração
(2010) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132010001300011
Pediatric Venous Thromboembolism
Branchford, B. R., & Goldenberg, N. A. (2012) · Springer eBooks · doi:10.1007/978-3-642-02202-9_337
Treatment of antiphospholipid syndrome
Sciascia, S., & Khamashta, M. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814551-7.00065-9
(2016) · VASA · doi:10.1024/0301-1526/a000487
Tromeur, C., & Couturaud, F. (2012) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(12)70192-1
Differenzialdiagnose und Behandlung des akuten Kopfschmerzes
Rabe, K., & Kastrup, O. (2013) · Humanmedizin kompakt · doi:10.1007/s40355-012-0008-8
Common Clinical Indications for Anticoagulation
Krishnamoorthy, S., Khoo, C. W., Shantsila, E., & Lip, G. Y. H. (2013) · doi:10.1007/978-1-908517-96-8_2
CrossRef Listing of Deleted DOIs
(2007) · CrossRef Listing of Deleted DOIs · doi:10.1007/s11932-004-0005-1
Hull, R. D., & Pineo, G. F. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1367-1.00062-8
Zotz, R. B., Sucker, C., Gerhardt, A., Diehm, C., Nüllen, H., & Noppeney, T. (2014) · Springer eBooks · doi:10.1007/978-3-642-21496-7_4
Anticoagulation: Held Too Long
(2014) · AORN Journal · doi:10.1016/j.aorn.2014.06.013
Differenzialdiagnose und Behandlung des akuten Kopfschmerzes
Rabe, K., & Kastrup, O. (2013) · Springer eBooks · doi:10.1007/978-3-642-40720-8_7
Liebman, H. A., & Weitz, I. C. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5223-4.00037-8
(2004) · British journal of surgery · doi:10.1002/bjs.4553
Comerota, A. J. (2011) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2011.06.017
Antiphospholipid Antibody Syndrome
Zambon, M., Cappelli, D., & Berlot, G. (2012) · Springer eBooks · doi:10.1007/978-88-470-2448-9_13 · Cited by 1
First National Congress Great, Italy. Rome, 19-21 October 2010
Editors, T. M. A. F. C. D. (2011) · Emergency Care Journal · doi:10.4081/ecj.2011.2.22
Optimal quality of vitamin K antagonist therapy in Japanese patients with venous thromboembolism
Hiramori, S., Yamashita, Y., Morimoto, T., Kadota, K., Takase, T., Kim, K., Oi, M., Akao, M., Kobayashi, Y., Toyofuku, M., et al. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.07.001
Galanaud, J. ‐. (2022) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2022.07.008
Venous infarction due to developmental venous anomaly with arteriovenous shunt
Gonmori‐Ohta, C., Hirotsu, T., Gomi, T., Matsushima, S., Nonaka, Y., & Akiyama, M. (2023) · Pediatrics International · doi:10.1111/ped.15484
Vrotniakaite-Bajerciene, K., Rütsche, S., Calzavarini, S., Quarroz, C., Stalder, O., Méan, M., Righini, M., Staub, D., Beer, J. H., Frauchiger, B., et al. (2023) · Preprints.org · doi:10.20944/preprints202307.1450.v1
Resolving the Gap in Evidence on the Role of Warfarin in Venous Thromboembolism Management in Japan
Sugimura, K. (2023) · Circulation Journal · doi:10.1253/circj.cj-23-0582
bshabshe, A. A. A. A., Nadeem, M., Assiri, A. M., Wani, J. I., Aziz, S., Sabah, Z. U., Alqahtani, N. A., Alshehri, F., Alshubily, R. F., & Alqahtani, A. M. (2023) · Advances in Biomedical and Health Sciences · doi:10.4103/abhs.abhs_13_23
Vitamin K Antagonists and Novel Oral Anticoagulant
Agnelli, G., & Becattini, C. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-287-8_14
Pediatric Venous Thromboembolism
(2018) · Frontiers research topics · doi:10.3389/978-2-88945-639-0
HEART's Selection 急性肺血栓塞栓症の内科的治療―薬物的抗血栓療法を中心に
真潮, 中. (2008) · 心臓 · doi:10.11281/shinzo1969.40.10_816
Cheung, C. K. M., Carlin, S., Scheier, T., Yi, Q., Chan, N., Bhagirath, V. C., Petropoulos, J., Wong, R. S. M., Weitz, J. I., & Eikelboom, J. W. (2026) · TH Open · doi:10.1055/a-2798-0066
Self-citationPrescribing patterns of apixaban and rivaroxaban for extended-phase anticoagulant therapy
Patel, M., Mei, C., Shapiro, N. L., & Uppuluri, E. M. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag026
Anticoagulants and Thrombolytics
Mones, J. V., Sharda, A. V., Lech, T. K., & Zwicker, J. I. (2026) · Springer eBooks · doi:10.1007/978-3-032-13858-3_47
Innovative Modeling and Simulation in Thrombosis and Hemostasis: Enhancing Diagnosis and Treatment
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8699-0
Drug Selection for Long-Term Anticoagulant Therapy in Patients with Venous Thromboembolism
Rylnikov, D. V., Loginovskaya, E. V., An, E. S., Seliverstov, E. I., & Zolotukhin, I. A. (2026) · Journal of Venous Disorders · doi:10.17116/flebo202620031258
Krebs, J. R., Wakefield, T., & Jacobs, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-28432-8.00048-x
Diagnóstico y tratamiento de la tromboembolia venosa
Minichiello, T., & Fogarty, P. (2008) · Clínicas médicas de Norteamérica
Duration of Anticoagulant Therapy After Venous Thromboembolism
Kearon, C. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-235-3_19
“... was subsequently tested in a double-blind trial of patients with unprovoked VTE, the lower intensity of anticoagulation was less effective in preventing recurrent VTE (intention-to-treat analysis: 1.9% vs. 0.7% per patient-year; hazard ratio 2.8 [95% CI 1.1–7.0]) and was associated with the same frequency of major…”
BackgroundInfluentialSelf-citationTherapie der Beinvenenthrombose
Bauersachs, R. M. (2004) · Der Internist · doi:10.1007/s00108-004-1302-8
“OAK mit INR 1,5–2,0; ELATE-Trial [16]: Vergleich INR 1,5–1,9 vs.”
Background
Metadata
- Authors
- Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., Turpie, A. G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S. R., Kassis, J., Rodger, M., Hambleton, J., & Gent, M.
- Affiliations
- McMaster University (CA)
- Western University (CA)
- Dalhousie University (CA)
- University of Ottawa (CA)
- University of New Brunswick (CA)
- University of Toronto (CA)
- McGill University (CA)
- Université Laval (CA)
- Université de Montréal (CA)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-14
- Volume
- 349
- Issue
- 7
- Pages
- 631-639
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2009013630
- Cited by
- 751
- References
- 12
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 3 · 2023: 12 · 2022: 8 · 2021: 12 · 2020: 17 · 2019: 25 · 2018: 38 · 2017: 26 · 2016: 29 · 2015: 27 · 2014: 31 · 2013: 58 · 2012: 45
- FWCI
- 34.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, low-intensity anticoagulation, venous thromboembolism, recurrent venous thromboembolism, unprovoked venous thromboembolism, international normalized ratio, bleeding risk, anticoagulation intensity, long-term prophylaxis
- MeSH terms
- Age Factors, Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Risk Factors, Warfarin, Treatment Outcome, International Normalized Ratio, Venous Thrombosis, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.